Skip to main content

Advertisement

SpringerLink
Log in

Update on Oxalate Crystal Disease

  • CRYSTAL ARTHRITIS (MH PILLINGER, SECTION EDITOR)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Oxalate arthropathy is a rare cause of arthritis characterized by deposition of calcium oxalate crystals within synovial fluid. This condition typically occurs in patients with underlying primary or secondary hyperoxaluria. Primary hyperoxaluria constitutes a group of genetic disorders resulting in endogenous overproduction of oxalate, whereas secondary hyperoxaluria results from gastrointestinal disorders associated with fat malabsorption and increased absorption of dietary oxalate. In both conditions, oxalate crystals can deposit in the kidney leading to renal failure. Since oxalate is primarily renally eliminated, it accumulates throughout the body in renal failure, a state termed oxalosis. Affected organs can include bones, joints, heart, eyes, and skin. Since patients can present with renal failure and oxalosis before the underlying diagnosis of hyperoxaluria has been made, it is important to consider hyperoxaluria in patients who present with unexplained soft tissue crystal deposition. The best treatment of oxalosis is prevention. If patients present with advanced disease, treatment of oxalate arthritis consists of symptom management and control of the underlying disease process.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Hoppe B, Beck BB, Milliner DS. The primary hyperoxalurias. Kidney Int. 2009;75(12):1264–71.

    Article  PubMed  CAS  Google Scholar 

  2. van Woerden CS, Groothoff JW, Wanders RJ, Davin JC, Wijburg FA. Primary hyperoxaluria type 1 in the netherlands: Prevalence and outcome. Nephrol Dial Transplant. 2003;18(2):273–9.

    Article  PubMed  Google Scholar 

  3. •• Hoppe B. An update on primary hyperoxaluria. Nat Rev Nephrol. 2012;8(8):467–75. An excellent review of primary hyperoxaluria.

    Article  PubMed  CAS  Google Scholar 

  4. Lieske JC, Monico CG, Holmes WS, Bergstralh EJ, Slezak JM, Rohlinger AL, et al. International registry for primary hyperoxaluria. Am J Nephrol. 2005;25(3):290–6.

    Article  PubMed  Google Scholar 

  5. •• Belostotsky R, Seboun E, Idelson GH, Milliner DS, Becker-Cohen R, Rinat C, et al. Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet. 2010;87(3):392–9. Initial description of the genetic mutations responsible for primary hyperoxaluria type 3.

    Article  PubMed  CAS  Google Scholar 

  6. • Monico CG, Rossetti S, Belostotsky R, Cogal AG, Herges RM, Seide BM, et al. Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol. 2011;6(9):2289–95. A study suggesting that genetic mutations involved in primary hyperoxaluria type 3 may also be a risk factor for idiopathic kidney stones.

    Article  PubMed  CAS  Google Scholar 

  7. Riedel TJ, Knight J, Murray MS, Milliner DS, Holmes RP, Lowther WT. 4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition. Biochim Biophys Acta. 2012;1822(10):1544–52.

    Article  PubMed  CAS  Google Scholar 

  8. Cornelis T, Bammens B, Lerut E, Cosyn L, Goovaerts G, Westhovens R, et al. AA amyloidosis due to chronic oxalate arthritis and vasculitis in a patient with secondary oxalosis after jejunoileal bypass surgery. Nephrol Dial Transplant. 2008;23(10):3362–4.

    Article  PubMed  Google Scholar 

  9. Dobbins JW, Binder HJ. Importance of the colon in enteric hyperoxaluria. N Engl J Med. 1977;296(6):298–301.

    Article  PubMed  CAS  Google Scholar 

  10. •• Kumar R, Lieske JC, Collazo-Clavell ML, Sarr MG, Olson ER, Vrtiska TJ, et al. Fat malabsorption and increased intestinal oxalate absorption are common after roux-en-Y gastric bypass surgery. Surgery. 2011;149(5):654–61. A study decribing the incidence of increased oxalate absorption following bariatric surgery.

    Article  PubMed  Google Scholar 

  11. Dobbins JW, Binder HJ. Effect of bile salts and fatty acids on the colonic absorption of oxalate. Gastroenterology. 1976;70(6):1096–100.

    PubMed  CAS  Google Scholar 

  12. Hylander E, Jarnum S, Jensen HJ, Thale M. Enteric hyperoxaluria: Dependence on small intestinal resection, colectomy, and steatorrhoea in chronic inflammatory bowel disease. Scand J Gastroenterol. 1978;13(5):577–88.

    Article  PubMed  CAS  Google Scholar 

  13. Hueppelshaeuser R, von Unruh GE, Habbig S, Beck BB, Buderus S, Hesse A, et al. Enteric hyperoxaluria, recurrent urolithiasis, and systemic oxalosis in patients with Crohn's disease. Pediatr Nephrol. 2012;27(7):1103–9.

    Article  PubMed  Google Scholar 

  14. Ciacci C, Spagnuolo G, Tortora R, Bucci C, Franzese D, Zingone F, et al. Urinary stone disease in adults with celiac disease: Prevalence, incidence and urinary determinants. J Urol. 2008;180(3):974–9.

    Article  PubMed  Google Scholar 

  15. Cartery C, Faguer S, Karras A, Cointault O, Buscail L, Modesto A, et al. Oxalate nephropathy associated with chronic pancreatitis. Clin J Am Soc Nephrol. 2011;6(8):1895–902.

    Article  PubMed  Google Scholar 

  16. • Rahman N, Hitchcock R. Case report of paediatric oxalate urolithiasis and a review of enteric hyperoxaluria. J Pediatr Urol. 2010;6(2):112–6. A review of enteric hyperoxaluria in children.

    Article  PubMed  CAS  Google Scholar 

  17. Nasr SH, D'Agati VD, Said SM, Stokes MB, Largoza MV, Radhakrishnan J, et al. Oxalate nephropathy complicating roux-en-Y gastric bypass: An underrecognized cause of irreversible renal failure. Clin J Am Soc Nephrol. 2008;3(6):1676–83.

    Article  PubMed  Google Scholar 

  18. Sinha MK, Collazo-Clavell ML, Rule A, Milliner DS, Nelson W, Sarr MG, et al. Hyperoxaluric nephrolithiasis is a complication of roux-en-Y gastric bypass surgery. Kidney Int. 2007;72(1):100–7.

    Article  PubMed  CAS  Google Scholar 

  19. • Pang R, Linnes MP, O'Connor HM, Li X, Bergstralh E, Lieske JC. Controlled metabolic diet reduces calcium oxalate supersaturation but not oxalate excretion after bariatric surgery. Urology. 2012;80(2):250–4. A study outlining the limitations of a low-oxalate diet alone following bariatric surgery.

    Article  PubMed  Google Scholar 

  20. Penniston KL, Kaplon DM, Gould JC, Nakada SY. Gastric band placement for obesity is not associated with increased urinary risk of urolithiasis compared to bypass. J Urol. 2009;182(5):2340–6.

    Article  PubMed  CAS  Google Scholar 

  21. Duffey BG, Pedro RN, Makhlouf A, Kriedberg C, Stessman M, Hinck B, et al. Roux-en-Y gastric bypass is associated with early increased risk factors for development of calcium oxalate nephrolithiasis. J Am Coll Surg. 2008;206(3):1145–53.

    Article  PubMed  Google Scholar 

  22. Froeder L, Arasaki CH, Malheiros CA, Baxmann AC, Heilberg IP. Response to dietary oxalate after bariatric surgery. Clin J Am Soc Nephrol. 2012;7(12):2033–40.

    Article  PubMed  CAS  Google Scholar 

  23. Ehlers SM, Posalaky Z, Strate RG, Quattlebaum FW. Acute reversible renal failure following jejunoileal bypass for morbid obesity: A clinical and pathological (EM) study of a case. Surgery. 1977;82:629–34.

    PubMed  CAS  Google Scholar 

  24. Verani R, Nasir M, Foley R. Granulomatous interstitial nephritis after a jejunoileal bypass: An ultrastructural and histochemical study. Am J Nephrol. 1989;9(1):51–5.

    Article  PubMed  CAS  Google Scholar 

  25. Sarica K, Akarsu E, Erturhan S, Yagci F, Aktaran S, Altay B. Evaluation of urinary oxalate levels in patients receiving gastrointestinal lipase inhibitor. Obesity (Silver Spring). 2008;16(7):1579–84.

    Article  CAS  Google Scholar 

  26. Karamadoukis L, Shivashankar GH, Ludeman L, Williams AJ. An unusual complication of treatment with orlistat. Clin Nephrol. 2009;71(4):430–2.

    PubMed  CAS  Google Scholar 

  27. Hatch M, Freel RW. Intestinal transport of an obdurate anion: Oxalate. Urol Res. 2005;33(1):1–16.

    Article  PubMed  CAS  Google Scholar 

  28. Hatch M, Cornelius J, Allison M, Sidhu H, Peck A, Freel RW. Oxalobacter sp. Reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int. 2006;69(4):691–8.

    Article  PubMed  CAS  Google Scholar 

  29. Hatch M, Freel RW, Vaziri ND. Regulatory aspects of oxalate secretion in enteric oxalate elimination. J Am Soc Nephrol. 1999;10 Suppl 14:S324–8.

    PubMed  CAS  Google Scholar 

  30. Jacobsen D, Hewlett TP, Webb R, Brown ST, Ordinario AT, McMartin KE. Ethylene glycol intoxication: Evaluation of kinetics and crystalluria. Am J Med. 1988;84(1):145–52.

    Article  PubMed  CAS  Google Scholar 

  31. Brent J, McMartin K, Phillips S, Burkhart KK, Donovan JW, Wells M, et al. Fomepizole for the treatment of ethylene glycol poisoning. Methylpyrazole for toxic alcohols study group. N Engl J Med. 1999;340(11):832–8.

    Article  PubMed  CAS  Google Scholar 

  32. Sanz P, Reig R. Clinical and pathological findings in fatal plant oxalosis. A review. The American journal of forensic medicine and pathology. 1992;13(4):342–5.

    Article  PubMed  CAS  Google Scholar 

  33. Barceloux DG. Rhubarb and oxalosis (rheum species). Dis Mon. 2009;55(6):403–11.

    Article  PubMed  Google Scholar 

  34. Lieske JC, Swift HS, Martin T, Patterson B, Toback FG. Renal epithelial cells rapidly bind and internalize calcium oxalate monohydrate crystals. ProcNatlAcadSci, USA. 1994;91:6987–91.

    Article  CAS  Google Scholar 

  35. Lieske JC, Toback FG. Regulation of renal epithelial cell endocytosis of calcium oxalate monohydrate crystals. Am J Physiol. 1993;264:F800–F7.

    PubMed  CAS  Google Scholar 

  36. Hammes MS, Lieske JC, Pawar S, Spargo BH, Toback FG. Calcium oxalate monohydrate crystals stimulate gene expression in renal epithelial cells. Kidney Int. 1995;48:501–9.

    Article  PubMed  CAS  Google Scholar 

  37. Lieske JC, Walsh-Reitz MM, Toback FG. Calcium oxalate monohydrate crystals are endocytosed by renal epithelial cells and induce proliferation. AmJPhysiol. 1992;262:F622–F30.

    CAS  Google Scholar 

  38. Lieske JC, Deganello S, Toback FG. Cell-crystal interactions and kidney stone formation. Nephron. 1999;81(S1):S8–S17.

    Article  Google Scholar 

  39. Khan SR, Finlayson B, Hackett RL. Scanning electron microscopy of calcium oxalate crystal formation in experimental nephrolithiasis. LabInvest. 1979;41:504–10.

    CAS  Google Scholar 

  40. Dykstra MJ, Hackett RL. Ultrastructural events in early calcium oxalate crystal formation in rats. Kidney Int. 1979;15:640–50.

    Article  PubMed  CAS  Google Scholar 

  41. Khan SR, Finlayson B, Hackett RL. Histologic study of the early events in oxalate induced intranephronic calculosis. InvestUrol. 1979;17:199–202.

    CAS  Google Scholar 

  42. Lieske JC, Spargo BH, Toback FG. Endocytosis of calcium oxalate crystals and proliferation of renal tubular epithelial cells in a patient with type 1 primary hyperoxaluria. J Urol. 1992;148(5):1517–9.

    PubMed  CAS  Google Scholar 

  43. •• Cochat P, Hulton SA, Acquaviva C, Danpure CJ, Daudon M, De Marchi M, et al. Primary hyperoxaluria type 1: Indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant. 2012;27(5):1729–36. A review of methods used to diagnose primary hyperoxaluria.

    Article  PubMed  CAS  Google Scholar 

  44. Kohn NN, Hughes RE, Mc Jr CD, Faires JS. The significance of calcium phosphate crystals in the synovial fluid of arthritic patients: The "pseudogout syndrome". II. Identification of crystals. Ann Intern Med. 1962;56:738–45.

    Article  PubMed  CAS  Google Scholar 

  45. Sarraf P, Kay J, Reginato AM. Non-crystalline and crystalline rheumatic disorders in chronic kidney disease. Curr Rheumatol Rep. 2008;10(3):235–48.

    Article  PubMed  CAS  Google Scholar 

  46. Verbruggen LA, Bourgain C, Verbeelen D. Late presentation and microcrystalline arthropathy in primary hyperoxaluria. Clin Exp Rheumatol. 1989;7(6):631–3.

    PubMed  CAS  Google Scholar 

  47. Rosenthal A, Ryan LM, McCarty DJ. Arthritis associated with calcium oxalate crystals in an anephric patient treated with peritoneal dialysis. Jama. 1988;260(9):1280–2.

    Article  PubMed  CAS  Google Scholar 

  48. Maldonado I, Prasad V, Reginato AJ. Oxalate crystal deposition disease. Curr Rheumatol Rep. 2002;4(3):257–64.

    Article  PubMed  Google Scholar 

  49. •• Bacchetta J, Fargue S, Boutroy S, Basmaison O, Vilayphiou N, Plotton I, et al. Bone metabolism in oxalosis: A single-center study using new imaging techniques and biomarkers. Pediatr Nephrol. 2010;25(6):1081–9. A study of bone imaging and FGF23 levels in patients with primary hyperoxaluria.

    Article  PubMed  Google Scholar 

  50. El Hage S, Ghanem I, Baradhi A, Mourani C, Mallat S, Dagher F, et al. Skeletal features of primary hyperoxaluria type 1, revisited. J Child Orthop. 2008;2(3):205–10.

    Article  PubMed  Google Scholar 

  51. Behnke B, Kemper MJ, Kruse HP, Muller-Wiefel DE. Bone mineral density in children with primary hyperoxaluria type I. Nephrol Dial Transplant. 2001;16(11):2236–9.

    Article  PubMed  CAS  Google Scholar 

  52. Aydin NE, Usta U. Oxalate deposition in tissues. Nephrol Dial Transplant. 2004;19(5):1323–4.

    Article  PubMed  Google Scholar 

  53. Bakshi NA, Al-Zahrani H. Bone marrow oxalosis. Blood. 2012;120(1):8.

    Article  PubMed  Google Scholar 

  54. Tapia G, Navarro JT, Navarro M. Leukoerythroblastic anemia due to oxalosis with extensive bone marrow involvement. Am J Hematol. 2008;83(6):515–6.

    Article  PubMed  Google Scholar 

  55. Mookadam F, Smith T, Jiamsripong P, Moustafa SE, Monico CG, Lieske JC, et al. Cardiac abnormalities in primary hyperoxaluria. Circ J. 2010;74(11):2403–9.

    Article  PubMed  Google Scholar 

  56. Van Driessche L, Dhondt A, De Sutter J. Heart failure with mitral valve regurgitation due to primary hyperoxaluria type 1: Case report with review of the literature. Acta Cardiol. 2007;62(2):202–6.

    Article  PubMed  Google Scholar 

  57. •• Blackmon JA, Jeffy BG, Malone JC, Knable Jr AL. Oxalosis involving the skin: Case report and literature review. Arch Dermatol. 2011;147(11):1302–5. A review of how oxalosis affects the skin.

    Article  PubMed  Google Scholar 

  58. Fielder AR, Garner A, Chambers TL. Ophthalmic manifestations of primary oxalosis. Br J Ophthalmol. 1980;64(10):782–8.

    Article  PubMed  CAS  Google Scholar 

  59. Munir WM, Sharma MC, Li T, Dealba F, Goldstein DA. Retinal oxalosis in primary hyperoxaluria type 1. Retina. 2004;24(6):974–6.

    Article  PubMed  Google Scholar 

  60. Small KW, Letson R, Scheinman J. Ocular findings in primary hyperoxaluria. Arch Ophthalmol. 1990;108(1):89–93.

    Article  PubMed  CAS  Google Scholar 

  61. Bilbao JM, Berry H, Marotta J, Ross RC. Peripheral neuropathy in oxalosis. A case report with electron microscopic observations. Can J Neurol Sci. 1976;3(1):63–7.

    PubMed  CAS  Google Scholar 

  62. Galloway G, Giuliani MJ, Burns DK, Lacomis D. Neuropathy associated with hyperoxaluria: Improvement after combined renal and liver transplantations. Brain Pathol. 1998;8(2):247–51.

    Article  PubMed  CAS  Google Scholar 

  63. Hall BM, Walsh JC, Horvath JS, Lytton DG. Peripheral neuropathy complicating primary hyperoxaluria. J Neurol Sci. 1976;29(2–4):343–9.

    Article  PubMed  CAS  Google Scholar 

  64. Moorhead PJ, Cooper DJ, Timperley WR. Progressive peripheral neuropathy in patient with primary hyperoxaluria. Br Med J. 1975;2(5966):312–3.

    Article  PubMed  CAS  Google Scholar 

  65. Mitsimponas KT, Wehrhan T, Falk S, Wehrhan F, Neukam FW, Schlegel KA. Oral findings associated with primary hyperoxaluria type I. J Craniomaxillofac Surg. 2012;40(8):e301–6.

    Article  PubMed  CAS  Google Scholar 

  66. Panis V, Tosios KI, Gagari E, Griffin TJ, Damoulis PD. Severe periodontitis in a patient with hyperoxaluria and oxalosis: A case report and review of the literature. J Periodontol. 2010;81(10):1497–504.

    Article  PubMed  Google Scholar 

  67. Rinksma AJ, Oosterhuis JW, Wolvius EB, van der Wal KG. Oral manifestations of oxalosis: A case report and review of the literature. J Oral Maxillofac Surg. 2008;66(9):1953–6.

    Article  PubMed  Google Scholar 

  68. Fishbein GA, Micheletti RG, Currier JS, Singer E, Fishbein MC. Atherosclerotic oxalosis in coronary arteries. Cardiovasc Pathol. 2008;17(2):117–23.

    Article  PubMed  CAS  Google Scholar 

  69. Tanriover B, Mejia A, Foster SV, Mubarak A. Primary hyperoxaluria involving the liver and hepatic artery: Images of an aggressive disease. Kidney Int. 2010;77(7):651.

    Article  PubMed  Google Scholar 

  70. Milliner DS, Eickholt JT, Bergstralh E, Wilson DM, Smith LH. Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. New Engl J Med. 1994;331:1553–8.

    Article  PubMed  CAS  Google Scholar 

  71. Mandell I, Krauss E, Millan JC. Oxalate-induced acute renal failure in Crohn's disease. AmJMed. 1980;69:628–32.

    CAS  Google Scholar 

  72. Earnest DL, Johnson G, Williams HE, Admirand WH. Hyperoxaluria in patients with ileal resection: An abnormality in dietary oxalate absorption. Gastroenterology. 1974;66(6):1114–22.

    PubMed  CAS  Google Scholar 

  73. Andersson H, Bosaeus I. Hyperoxaluria in malabsorptive states. Urol Int. 1981;36(1):1–9.

    Article  PubMed  CAS  Google Scholar 

  74. • Mulay SR, Kulkarni OP, Rupanagudi KV, Migliorini A, Darisipudi MN, Vilaysane A, et al. Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1beta secretion. J Clin Invest. 2013;123(1):236–46. A study demonstrating how calcium oxalate crystals induce IL-1β secretion.

    Article  PubMed  CAS  Google Scholar 

  75. Rankin AC, Walsh SB, Summers SA, Owen MP, Mansell MA. Acute oxalate nephropathy causing late renal transplant dysfunction due to enteric hyperoxaluria. Am J Transplant. 2008;8(8):1755–8.

    Article  PubMed  CAS  Google Scholar 

  76. Robijn S, Vervaet BA, Hoppe B, D'Haese PC, Verhulst A. Lanthanum carbonate inhibits intestinal oxalate absorption and prevents nephrocalcinosis after oxalate loading in rats. J Urol 2012 Dec 7.

  77. Lieske JC, Regnier C, Dillon JJ. Use of sevelamer hydrochloride as an oxalate binder. J Urol. 2008;179(4):1407–10.

    Article  PubMed  CAS  Google Scholar 

  78. Lieske JC, Goldfarb DS, De Simone C, Regnier C. Use of a probiotic to decrease enteric hyperoxaluria. Kidney Int. 2005;68(3):1244–9.

    Article  PubMed  CAS  Google Scholar 

  79. •• Lieske JC, Tremaine WJ, De Simone C, O'Connor HM, Li X, Bergstralh EJ, et al. Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation. Kidney Int. 2010;78(11):1178–85. A study investigating the role of diet and priobiotics on urinary oxalate excretion in patients with hyperoxaluria.

    Article  PubMed  CAS  Google Scholar 

  80. Gibbs DA, Watts RW. The action of pyridoxine in primary hyperoxaluria. Clin Sci. 1970;38(2):277–86.

    PubMed  CAS  Google Scholar 

  81. Watts RW, Veall N, Purkiss P, Mansell MA, Haywood EF. The effect of pyridoxine on oxalate dynamics in three cases of primary hyperoxaluria (with glycollic aciduria). Clin Sci. 1985;69(1):87–90.

    PubMed  CAS  Google Scholar 

  82. • Fargue S, Lewin J, Rumsby G, Danpure CJ. Four of the most common mutations in primary hyperoxaluria type 1 unmask the cryptic mitochondrial targeting sequence of alanine:glyoxylate aminotransferase encoded by the polymorphic minor allele. J Biol Chem 2012 Dec 10. A study showing how specific mutations result in mistargeting of the the peroxisomal enzyme alanine:glyoxylate aminotransferase (AGT) to mitochondria in primary hyperoxaluria.

  83. Monico CG, Rossetti S, Olson JB, Milliner DS. Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney Int. 2005;67(5):1704–9.

    Article  PubMed  CAS  Google Scholar 

  84. Illies F, Bonzel KE, Wingen AM, Latta K, Hoyer PF. Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1. Kidney Int. 2006;70(9):1642–8.

    Article  PubMed  CAS  Google Scholar 

  85. Franssen CF. Oxalate clearance by haemodialysis–a comparison of seven dialysers. Nephrol Dial Transplant. 2005;20(9):1916–21.

    Article  PubMed  CAS  Google Scholar 

  86. Hoppe B, Graf D, Offner G, Latta K, Byrd DJ, Michalk D, et al. Oxalate elimination via hemodialysis or peritoneal dialysis in children with chronic renal failure. Pediatr Nephrol. 1996;10(4):488–92.

    Article  PubMed  CAS  Google Scholar 

  87. Hoppe B, Langman CB. A united states survey on diagnosis, treatment, and outcome of primary hyperoxaluria. Pediatr Nephrol. 2003;18(10):986–91.

    Article  PubMed  Google Scholar 

  88. Hoppe B, Latta K, von Schnakenburg C, Kemper MJ. Primary hyperoxaluria−the german experience. Am J Nephrol. 2005;25(3):276–81.

    Article  PubMed  Google Scholar 

  89. • Cochat P, Fargue S, Harambat J. Primary hyperoxaluria type 1: Strategy for organ transplantation. Curr Opin Organ Transplant. 2010;15(5):590–3. An overview of transplant options for patients with primary hyeroxaluria.

    Article  PubMed  Google Scholar 

  90. •• Bergstralh EJ, Monico CG, Lieske JC, Herges RM, Langman CB, Hoppe B, et al. Transplantation outcomes in primary hyperoxaluria. Am J Transplant. 2010;10(11):2493–501. A study examining the outcome of transplantation in patients with primary hyperoxaluria over the past decade.

    Article  PubMed  CAS  Google Scholar 

  91. Monico CG, Milliner DS. Combined liver-kidney and kidney-alone transplantation in primary hyperoxaluria. Liver Transpl. 2001;7(11):954–63.

    Article  PubMed  CAS  Google Scholar 

  92. Allison MJ, Dawson KA, Mayberry WR, Foss JG. Oxalobacter formigenes gen. nov., sp. nov.: oxalate-degrading anaerobes that inhabit the gastrointestinal tract. Arch Microbiol. 1985;141(1):1–7.

    Article  PubMed  CAS  Google Scholar 

  93. Grujic D, Salido EC, Shenoy BC, Langman CB, McGrath ME, Patel RJ, et al. Hyperoxaluria is reduced and nephrocalcinosis prevented with an oxalate-degrading enzyme in mice with hyperoxaluria. Am J Nephrol. 2009;29(2):86–93.

    Article  PubMed  CAS  Google Scholar 

  94. •• Hatch M, Gjymishka A, Salido EC, Allison MJ, Freel RW. Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with oxalobacter. Am J Physiol Gastrointest Liver Physiol. 2011;300(3):G461–9. Examination of the beneficial effect of Oxalobacter in mice with primary hyperoxaluria.

    Article  PubMed  CAS  Google Scholar 

  95. Sidhu H, Schmidt ME, Cornelius JG, Thamilselvan S, Khan SR, Hesse A, et al. Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium oxalobacter formigenes: Possible prevention by gut recolonization or enzyme replacement therapy. J Am Soc Nephrol. 1999;10 Suppl 14:S334–40.

    PubMed  CAS  Google Scholar 

  96. Hatch M, Freel RW. Renal and intestinal handling of oxalate following oxalate loading in rats. Am J Nephrol. 2003;23(1):18–26.

    Article  PubMed  CAS  Google Scholar 

  97. Hoppe B, Beck B, Gatter N, von Unruh G, Tischer A, Hesse A, et al. Oxalobacter formigenes: A potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int. 2006;70(7):1305–11.

    Article  PubMed  CAS  Google Scholar 

  98. •• Hoppe B, Groothoff JW, Hulton SA, Cochat P, Niaudet P, Kemper MJ, et al. Efficacy and safety of oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Nephrology, dialysis, transplantation : Official publication of the european dialysis and transplant association. European Renal Association. 2011;26(11):3609–15. Lack of effect of Oxalobacter on urinary oxalate excretion in patients with primary hyperoxaluria.

    Google Scholar 

  99. • Salido E, Rodriguez-Pena M, Santana A, Beattie SG, Petry H, Torres A. Phenotypic correction of a mouse model for primary hyperoxaluria with adeno-associated virus gene transfer. Mol Ther. 2011;19(5):870–5. A study describing the successful treatment of hyperoxaluria in mice using gene transfer.

    Article  PubMed  CAS  Google Scholar 

  100. Hopper ED, Pittman AM, Fitzgerald MC, Tucker CL. In vivo and in vitro examination of stability of primary hyperoxaluria-associated human alanine:Glyoxylate aminotransferase. J Biol Chem. 2008;283(45):30493–502.

    Article  PubMed  CAS  Google Scholar 

  101. Lumb MJ, Birdsey GM, Danpure CJ. Correction of an enzyme trafficking defect in hereditary kidney stone disease in vitro. Biochem J. 2003;374(Pt 1):79–87.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors gratefully acknowledge the support of the Rare Kidney Stone Consortium (U54KD083908), a part of NIH Rare Diseases Clinical Research Network (RDCRN), funded by the NIDDK and the NIH Office of Rare Diseases Research (ORDR); the Mayo Clinic O’Brien Urology Research Center (P50 DK083007) funded by the NIDDK; the Mayo Clinic Hyperoxaluria Center; and the Oxalosis and Hyperoxaluria Foundation.

Conflict of interest

Elizabeth C. Lorenz declares that she has no conflict of interest.

Claude J. Michet declares that he has no conflict of interest.

Dawn S. Milliner has had travel/accommodations expenses covered/reimbursed by the Oxalosis and Hyperoxaluria Foundation.

John C. Lieske declares that he has no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA

    Elizabeth C. Lorenz, Dawn S. Milliner & John C. Lieske

  2. Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA

    Clement J. Michet

  3. Renal Laboratory, Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA

    John C. Lieske

Authors
  1. Elizabeth C. Lorenz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Clement J. Michet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dawn S. Milliner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John C. Lieske
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John C. Lieske.

Additional information

This article is part of the Topical Collection on Crystal Arthritis

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lorenz, E.C., Michet, C.J., Milliner, D.S. et al. Update on Oxalate Crystal Disease. Curr Rheumatol Rep 15, 340 (2013). https://doi.org/10.1007/s11926-013-0340-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-013-0340-4

Keywords

Search

Navigation